Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MIF | P14174 | 9/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669379 | 1.00 | CES1 (0.61) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL11089109 | 0.89 | TDP1 (0.69) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL8460792 | 0.88 | SRD5A1 (0.56) | CES1MIFMAOBMAPK14CYP26A1 | |
| SCHEMBL15676305 | 0.85 | MAOA (0.67) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL44496 | 0.82 | CES1 (0.90) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL29408351 | 0.82 | CES1 (0.90) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL29437756 | 0.82 | CES1 (0.90) | CES1MIFMAOBMAPK14TDP1 | |
| SCHEMBL4135475 | 0.81 | CES1 (0.61) | CES1MAOBMAPK14TDP1L3MBTL1 | |
| SCHEMBL2312578 | 0.81 | AKR1B1 (0.58) | MIFMAOBMAPK14AKR1B1CYP26A1 | |
| SCHEMBL4040922 | 0.81 | SRD5A1 (0.46) | CES1MIFMAOBMAPK14CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247541-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | Peptilogics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109456-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | LEE FRANCIS (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-01 | — | — | US | disclosed |
| US-9382288-B2 | Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2016-07-05 | — | — | US | disclosed |
| EP-2648707-B1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2648707-B1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9090535-B2 | Hydroxylated tricyclic compounds | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090535-B2 | Hydroxylated tricyclic compounds | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090535-B2 | Hydroxylated tricyclic compounds | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130317114-A1 | Hydroxylated Tricyclic Compounds | NEKTAR THERAPEUTICS (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012079017-A1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012079017-A1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| EP-1519915-B1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5442122-A | Peptide amide linker | SHIMADZU CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0597400-A1 | Dibenzosuberyl and dibenzosuberenyl derivatives and their use as linker groups | SHIMADZU CORPORATION (JP) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | CES1 439/4885MIF 1642/4885MAOB 2154/4885 |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | CES1 284/4885MIF 2393/4885MAOB 1261/4885 |
| US-20130317114-A1 | Hydroxylated Tricyclic Compounds | ABCG2, UGT1A1, HTT | CES1 1345/4885MIF 1282/4885MAOB 439/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | CES1 435/4885MIF 1592/4885MAOB 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.